Pluri is a biotech firm that develops and applies advanced cell expansion platforms to support the creation and manufacture of cell-based products across multiple sectors including pharmaceuticals, regenerative medicine, food technology and agriculture. At the core of its operations is a proprietary three-dimensional (3D) cell expansion technology designed to grow cells efficiently and at scale. Pluri leverages this technology through its PluriCDMO™ division to offer contract development and manufacturing services, helping partners bring complex biological therapies from early research through to clinical and commercial stages. The company operates globally, with activity spanning Israel, the United States and the European Union, and engages in collaborative ventures that widen the application of its cell expansion platforms.

Key products and services

3D cell expansion platforms: Proprietary technology to grow various cell types, applied in drug development, regenerative therapies and beyond.

PluriCDMO™ contract development and manufacturing services: Full-service support from preclinical development to commercial manufacturing of cell-based therapies, including process development, scale-up, validation and logistics.

Cell-based therapeutic development support: Expertise and facilities to manufacture clinical-grade batches of advanced therapies.

Applications in food and agriculture: Use of cell technology to develop solutions such as cultivated foods and plant resilience enhancements.

Pluri combines decades of technological innovation with a collaborative network of ventures to address unmet needs in healthcare, sustainability and bio-manufacturing. Through its scalable cell expansion systems and CDMO services, the company aims to lower barriers to the development and production of complex biological products, while expanding the reach of cell-based technologies into new markets and applications.